Items where authors include "Parker, B"

Article

Khoo, SH, FitzGerald, R, Saunders, G et al. (87 more authors) (2022) Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O, Abbas, A, Abbas, F et al. (6300 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 399 (10325). pp. 665-676. ISSN 0140-6736

Galloway, J, Edwards, J, Bhagat, S et al. (7 more authors) (2021) Direct healthcare resource utilisation, health-related quality of life, and work productivity in patients with moderate rheumatoid arthritis: an observational study. BMC Musculoskeletal Disorders, 22 (1). 277. ISSN 1471-2474

Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736

Kim, HU, Alten, R, Cummings, F et al. (14 more authors) (2021) Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs, 13 (1). 1868078. ISSN 1942-0862

McCarthy, EM, Sutton, E, Nesbit, S et al. (18 more authors) (2018) Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 57 (3). pp. 470-479. ISSN 1462-0324

McCarthy, EM, Sutton, E, Nesbit, S et al. (18 more authors) (2017) Corrigendum: The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. Rheumatology, 56 (6). p. 1049. ISSN 1462-0324

McCarthy, EM, Sutton, E, Nesbit, S et al. (18 more authors) (2017) The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. Rheumatology, 56 (6). pp. 1041-1043. ISSN 1462-0324